-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyzing ITeos Therapeutics (NASDAQ:ITOS) and Vigil Neuroscience (NASDAQ:VIGL)
Analyzing ITeos Therapeutics (NASDAQ:ITOS) and Vigil Neuroscience (NASDAQ:VIGL)
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
Profitability
This table compares iTeos Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.
Get iTeos Therapeutics alerts:Net Margins | Return on Equity | Return on Assets | |
iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
Vigil Neuroscience | N/A | -55.45% | -38.74% |
Analyst Recommendations
This is a summary of current recommendations for iTeos Therapeutics and Vigil Neuroscience, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
Vigil Neuroscience | 0 | 1 | 5 | 0 | 2.83 |
Valuation & Earnings
This table compares iTeos Therapeutics and Vigil Neuroscience's revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
iTeos Therapeutics | $344.77 million | 2.23 | $214.52 million | $6.88 | 3.15 |
Vigil Neuroscience | N/A | N/A | -$43.28 million | ($9.99) | -1.22 |
iTeos Therapeutics has higher revenue and earnings than Vigil Neuroscience. Vigil Neuroscience is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
88.9% of Vigil Neuroscience shares are held by institutional investors. 6.5% of iTeos Therapeutics shares are held by insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
iTeos Therapeutics beats Vigil Neuroscience on 7 of the 11 factors compared between the two stocks.
About iTeos Therapeutics
(Get Rating)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
About Vigil Neuroscience
(Get Rating)
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.
ITOS治療公司(納斯達克:ITOS-GET評級)和維吉爾神經科學(納斯達克:VIGL-GET評級)都是小盤醫療公司,但哪種投資更好?我們將根據兩家公司的風險、股息、分析師建議、機構所有權、估值、收益和盈利能力的強弱對它們進行比較。
Profitability
盈利能力
This table compares iTeos Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.
此表比較了iTeos Treeutics和Vigil NeuroScience的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
iTeos Therapeutics | 57.48% | 42.62% | 31.39% |
Vigil Neuroscience | N/A | -55.45% | -38.74% |
淨利潤率 | 股本回報率 | 資產回報率 | |
ITeos治療公司 | 57.48% | 42.62% | 31.39% |
守夜神經科學 | 不適用 | -55.45% | -38.74% |
Analyst Recommendations
分析師建議
This is a summary of current recommendations for iTeos Therapeutics and Vigil Neuroscience, as provided by MarketBeat.com.
這是由MarketBeat.com提供的對iTeos治療公司和Vigil神經科學公司的當前建議的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
iTeos Therapeutics | 0 | 0 | 0 | 0 | N/A |
Vigil Neuroscience | 0 | 1 | 5 | 0 | 2.83 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
ITeos治療公司 | 0 | 0 | 0 | 0 | 不適用 |
守夜神經科學 | 0 | 1 | 5 | 0 | 2.83 |
Valuation & Earnings
估值與收益
This table compares iTeos Therapeutics and Vigil Neuroscience's revenue, earnings per share (EPS) and valuation.
此表比較了iTeos Treeutics和Vigil NeuroScience的收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
iTeos Therapeutics | $344.77 million | 2.23 | $214.52 million | $6.88 | 3.15 |
Vigil Neuroscience | N/A | N/A | -$43.28 million | ($9.99) | -1.22 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
ITeos治療公司 | 3.4477億美元 | 2.23 | 2.1452億美元 | $6.88 | 3.15 |
守夜神經科學 | 不適用 | 不適用 | -4,328萬元 | ($9.99) | -1.22 |
iTeos Therapeutics has higher revenue and earnings than Vigil Neuroscience. Vigil Neuroscience is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
ITeos治療公司的收入和收益比Vigil神經科學公司高。維吉爾神經科學的市盈率低於iTeos治療公司,這表明它目前是兩隻股票中更負擔得起的一隻。
Institutional and Insider Ownership
機構和內部人持股
88.9% of Vigil Neuroscience shares are held by institutional investors. 6.5% of iTeos Therapeutics shares are held by insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Vigil NeuroScience 88.9%的股份由機構投資者持有。ITeos治療公司6.5%的股份由內部人士持有。相比之下,Vigil NeuroScience 46.6%的股份由內部人士持有。強大的機構持股表明,對衝基金、大型基金管理公司和捐贈基金相信,一家公司的長期表現將好於大盤。
Summary
摘要
iTeos Therapeutics beats Vigil Neuroscience on 7 of the 11 factors compared between the two stocks.
在兩隻股票之間的11個因素中,iTeos治療公司在7個因素上擊敗了Vigil NeuroScience。
About iTeos Therapeutics
關於iTeos治療公司
(Get Rating)
(獲取評級)
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
ITeos治療公司是一家臨牀階段的生物製藥公司,致力於為患者發現和開發免疫腫瘤療法。該公司的產品線包括處於第二階段臨牀試驗的腺苷A2AR拮抗劑的小分子拮抗劑InupAdant,以及處於第1/2階段臨牀試驗的TIGIT或具有Ig和ITIM結構域的T細胞免疫受體拮抗劑EOS-448,以及用於激活樹突狀細胞和巨噬細胞並促進抗體依賴的細胞毒性或ADCC活性的Fc?R。ITeos治療公司成立於2011年,總部設在馬薩諸塞州沃特敦。
About Vigil Neuroscience
關於維吉爾神經科學
(Get Rating)
(獲取評級)
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
維吉爾神經科學公司是一家專注於小膠質細胞的公司,致力於為受到罕見和常見神經退行性疾病影響的患者、照顧者和家庭開發疾病修正療法。它的主要候選產品是VGL101,這是一種完全人類的單抗(MAb),旨在激活髓樣細胞2(TREM2)上表達的觸發受體,該受體處於I期,用於治療成人起病的軸突球體和有色膠質細胞,以及治療大腦腎上腺腦白質營養不良和阿爾茨海默病。該公司還開發了一種適合口服的小分子TREM2激動劑,用於治療與小膠質細胞功能障礙相關的常見神經退行性疾病。維吉爾神經科學公司成立於2020年,總部設在馬薩諸塞州劍橋市。維吉爾神經科學公司是安進的子公司。
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受iTeos治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對iTeos治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧